Results 71 to 80 of about 3,759,163 (248)

Molecular Profiling of Prostate Cancer Patients [PDF]

, 2009
In the UK, more than 30 000 men are diagnosed annually with prostate cancer (PCa) and about 10 000 men die from it each year. Although several molecular markers have been associated with prostate cancer development and/ or progression, only few of them
Nna, Emmanuel Okechukwu
core   +3 more sources

Irradiation of prostate cancer alters circulating small extracellular vesicle functions

Scientific Reports
It is known that β1 integrins and a downstream signaling molecule c-Src are upregulated in prostate cancer (PrCa) tissues, are co-expressed in circulating small extracellular vesicles (sEVs) and contribute to cancer progression. Here, we demonstrate that
Aejaz Sayeed, Vaughn Garcia, Cecilia E. Verrillo, Rachel M. DeRita, Md Niamat Hossain, Shiv Ram Krishn, Samuel Sey, Christopher D. Shields, Adrian D. Altieri, Qin Liu, Khalid Sossey-Alaoui, William K. Kelly, Lucia R. Languino   +12 more
doaj   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Five years of prostate cancer: research and collaboration [PDF]

, 2010
The Prostate Cancer Research Consortium (PCRC) was established at the end of 2003, through a significant competitive grant from the Irish Cancer Society, with the stated aim of linking “like minded” researchers from different academic institutions ...
Lawlor, Mark, Watson, William R, Prostate Cancer Research Consortium   +2 more
core  

Genetic Association of the KLK4 Locus with Risk of Prostate Cancer [PDF]

, 2012
The Kallikrein-related peptidase, KLK4, has been shown to be significantly overexpressed in prostate tumours in numerous studies and is suggested to be a potential biomarker for prostate cancer.
Aitken, J F, Heathcote, P, Clements, J, Gardiner, Robert, Suzanne Chambers (138079), the Australian Prostate Cancer BioResource, Judith A Clements, Gardiner Robert A., Srilakshmi Srinivasan, Aitken, Joanne F, O’Mara Tracy, Marquart, Louise, Wood, G, Kerr, K, Gardiner, Robert A., O'Mara, Tracy, Spurdle, Amanda B, Chambers, Suzanne, Samaratunga, Hema, Felicity Lose, Eckert, A, Gardiner, Robert A, Australian Prostate Cancer BioResource, Louise Marquart (138077), Clements, Judith A, Srinivasan Srilakshmi, Aitken, Joanne F., Samaratunga, H, Clements, Judith A., Clements, J A, Clements, Judith, Marquart Louise, Batra, Jyotsna, Srinivasan, S, Srinivasan, Srilakshmi, O'Mara, T, Tracy O’Mara (138072), Amanda B Spurdle, Marquart, L, Felicity Lose (38909), Louise Marquart, Amanda B. Spurdle (47489), Malone, G, Lose Felicity, Aitken Joanne F., Batra Jyotsna, Suzanne Chambers, Robert A Gardiner, Spurdle, A B, Robert A. Gardiner (138083), Turner, M, Tracy O'Mara, Joanne F Aitken, Chambers Suzanne, Gardiner, R A, Batra, J, Collins, A, Yeadon, T, Clements Judith A., Spurdle, Amanda B., Srilakshmi Srinivasan (138067), Spurdle Amanda B., Jyotsna Batra (138092), Lose, Felicity, Saunders, P, Jyotsna Batra, Chambers, S, Joanne F. Aitken (138087), Judith A. Clements (138096)   +68 more
core   +3 more sources

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Impact of COVID-19 on the time to counseling and treatment of prostate cancer

The Aging Male
Purpose This study investigates how the COVID-19 pandemic (CP) impacted the timeline between initial diagnosis (ID) of prostate carcinoma and subsequent therapy consultation (TC) or radical prostatectomy (RP) due to the implementation of a “minimal ...
Dejan K. Filipas, Randi M. Pose, Phillip Marks, Pierre Tennstedt, Burkhard Beyer, Derya Tilki, Hendrik Isbarn, Tobias Maurer, Tim A. Ludwig, Hans Heinzer, Thomas Steuber   +10 more
doaj   +1 more source

The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

Diagnostics, 2020
Radical prostatectomy (RP) is a curatively intended treatment option for clinically localized non-metastatic prostate cancer (PCa). Novel biomarkers could refine treatment choice based on a better identification of men at risk of biochemical recurrence ...
Hein Vincent Stroomberg, Gitte Kristensen, Kasper Drimer Berg, Solvej Lippert, Klaus Brasso, Martin Andreas Røder   +5 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer [PDF]

European Medical Journal Oncology, 2014
Prostate cancer (PrCa) is the most common cancer type in men in developed countries. In the last few years, a dramatic change has occurred in the understanding of castration-resistant PrCa which has led to the development of new drugs that have an impact
Elena Castro, Nuria Romero, David Olmos
doaj